Development and validation of a UPLC–MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver-Reference-Cited by-同舟云学术

Development and validation of a UPLC–MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver

Published:2016-07 Issue:13 Volume:8 Page:1353-1363
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Ocque Andrew J¹,Hagler Colleen E¹,Difrancesco Robin¹,Woolwine-Cunningham Yvonne²,Bednasz Cindy J¹,Morse Gene D¹,Talal Andrew H³

Affiliation:

1. Translational Pharmacology Research Core, Department of Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, New York State Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, Buffalo, NY, USA

2. Clinical & Translational Research Center, University at Buffalo, Buffalo, NY, USA

3. Division of Gastroenterology & Hepatology & Center for Clinical & Research in Liver Disease, Jacobs School of Medicine, University at Buffalo, Buffalo, NY, USA

Abstract

Aim: Determination of paritaprevir and ritonavir in rat liver tissue samples. Results: We successfully validated a UPLC–MS/MS method to measure paritaprevir and ritonavir in rat liver using deuterated internal standards (d8-paritapervir and d6-ritonavir). The method is linear from 20 to 20,000 and 5 to 10,000 pg on column for paritaprevir and ritonavir, respectively, and is normalized per milligram tissue. Interday and intraday variability ranged from 0.591 to 5.33% and accuracy ranged from -6.68 to 10.1% for quality control samples. The method was then applied to the measurement of paritaprevir and ritonavir in rat liver tissue samples from a pilot study. Conclusion: The validated method is suitable for measurement of paritaprevir and ritonavir within rat liver tissue samples for PK studies.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

http://www.future-science.com/doi/pdf/10.4155/bio-2016-0040

Reference30 articles.

1. World Health Organization. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection (2014). http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf.

2. Hepatitis C virus infection in USA: an estimate of true prevalence

3. Centers for Disease Control and Prevention. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis Infection. Transmission and Symptoms.www.cdc.gov/hepatitis/hcv/hcvfaq.htm#b2.

4. Centers for Disease Control and Prevention. Viral Hepatitis. CDC Recommendations for Specific Populations and Settings. www.cdc.gov/hepatitis/populations/hiv.htm.

5. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous Estimation of Ombitasvir, Paritaprevir and Ritonavir in Tablet Dosage Form by Reverse Phase High-Performance Liquid Chromatography;International Journal of Life Science and Pharma Research;2022-07-15

2. Analytical Techniques for the Analysis of Lopinavir and Ritonavir in Pharmaceutical Dosage Form and Biological Matrices: A Review;Current Pharmaceutical Analysis;2021-12-17

3. Combining subsidiary and synchronous approaches for concurrent spectrofluorimetric assurance of lopinavir and ritonavir in tablets utilized in convention for treatment of coronavirus infection (COVID-19) and biological fluids;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2021-12

4. Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues;Talanta;2021-03

5. Development and Validation of a New LC–MS/MS Analytical Method for Direct-Acting Antivirals and Its Application in End-Stage Renal Disease Patients;European Journal of Drug Metabolism and Pharmacokinetics;2019-10-30